Elias Karl Mai

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5375504/publications.pdf

Version: 2024-02-01

		623188	500791
45	891	14	28
papers	citations	h-index	g-index

47	47	47	1818
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. Blood, 2016, 128, 1226-1233.	0.6	185
2	Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. Journal of Clinical Oncology, 2022, 40, 3406-3418.	0.8	115
3	Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial. Haematologica, 2015, 100, 964-969.	1.7	62
4	Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma. Blood Cancer Journal, 2021, 11, 1.	2.8	57
5	Single versus tandem highâ€dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: longâ€term results from the phase <scp>III GMMG</scp>â€<scp>HD</scp>2 trial. British Journal of Haematology, 2016, 173, 731-741.	1.2	50
6	Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. Leukemia, 2020, 34, 1853-1865.	3.3	47
7	A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma. Haematologica, 2015, 100, 818-825.	1.7	45
8	Analysis of longâ€term survival in multiple myeloma after firstâ€line autologous stem cell transplantation: impact of clinical risk factors and sustained response. Cancer Medicine, 2018, 7, 307-316.	1.3	42
9	Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma. American Journal of Hematology, 2016, 91, E473-E477.	2.0	27
10	Association between magnetic resonance imaging patterns and baseline disease features in multiple myeloma: analyzing surrogates of tumour mass and biology. European Radiology, 2016, 26, 3939-3948.	2.3	27
11	A systematic classification of death causes in multiple myeloma. Blood Cancer Journal, 2018, 8, 30.	2.8	26
12	Cytogenetic subclone formation and evolution in progressive smoldering multiple myeloma. Leukemia, 2020, 34, 1192-1196.	3.3	26
13	Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma: Results from the Randomized Phase III GMMG-HD6 Trial. Blood, 2021, 138, 486-486.	0.6	25
14	Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial. Blood, 2021, 138, 463-463.	0.6	19
15	Risk of Second Primary Cancers in Multiple Myeloma Survivors in German and Swedish Cancer Registries. Scientific Reports, 2016, 6, 22084.	1.6	15
16	Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities. Haematologica, 2022, 107, 1891-1901.	1.7	15
17	Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial. Haematologica, 2016, 101, e485-e487.	1.7	14
18	Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation. Haematologica, 2017, 102, 1432-1438.	1.7	14

#	Article	IF	Citations
19	Potential therapeutic targets in plasma cell disorders: A flow cytometry study. Cytometry Part B - Clinical Cytometry, 2017, 92, 145-152.	0.7	13
20	Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison. Immunotherapy, 2021, 13, 143-154.	1.0	9
21	Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma. Blood Cancer Journal, 2019, 9, 71.	2.8	7
22	Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial. Blood Cancer Journal, 2019, 9, 45.	2.8	7
23	Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age. Leukemia, 2021, 35, 809-822.	3.3	7
24	Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma. BMC Cancer, 2016, 16, 290.	1.1	5
25	Cytogenetic aberrations in multiple myeloma are associated with shifts in serum immunoglobulin isotypes distribution and levels. Haematologica, 2018, 103, e162-e164.	1.7	5
26	Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma. Leukemia, 2019, 33, 258-261.	3.3	5
27	Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial. Leukemia, 2021, 35, 3007-3011.	3.3	4
28	Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation. Clinical Cancer Research, 2020, 26, 5879-5886.	3.2	3
29	Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial. Cancers, 2021, 13, 4856.	1.7	3
30	Similar Quality of Life with 5mg Versus 25mg Lenalidomide Maintenance after First-Line High-Dose Therapy and Autologous Blood Stem Cell Transplantation for Multiple Myeloma: Results of the Lenamain Trial. Blood, 2018, 132, 2003-2003.	0.6	3
31	Bortezomib-Based Induction and Maintenance Overcomes the Negative Prognostic Impact of Renal Impairment and del17p in Transplant-Eligible Myeloma Patients: Long Term Results from the Phase III HOVON-65/GMMG-HD4 Study after Median 137 Months Follow up. Blood, 2019, 134, 3308-3308.	0.6	3
32	Clinical Risk Factors for Peripheral Neuropathy in Patients Treated with Subcutaneous or Intravenous Bortezomib for Newly Diagnosed Multiple Myeloma. Blood, 2015, 126, 4233-4233.	0.6	2
33	The Role of Clonal Evolution on Progression, Blood Parameters, and Response to Therapy in Multiple Myeloma. Frontiers in Oncology, 0, 12, .	1.3	2
34	Submyeloablative total body irradiationâ€based conditioning and allogeneic stem cell transplantation in highâ€risk myeloma with early progression after upâ€front autologous transplantation. British Journal of Haematology, 2021, , .	1.2	1
35	Subcutaneous Versus Intravenous Bortezomib in Two Different Induction Therapies for Newly Diagnosed Multiple Myeloma â€“ Subgroup Analysis from the GMMG-MM5 Trial. Blood, 2014, 124, 3475-3475.	0.6	1
36	Response After Induction Therapy in Transplant-eligible Newly-diagnosed Myeloma - a Pooled Analysis from Three Subsequent Multicenter PhaseÂIII Trials. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e76.	0.2	0

#	Article	IF	Citations
37	Comparison of bortezomib versus lenalidomide maintenance therapy in newly-diagnosed, transplant-eligible multiple myeloma: Results from the phase III GMMG-HD4 and -MM5 trials. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e43.	0.2	0
38	Normalization of serum free light chains during therapy in the MM5 trial predicts prolonged progression free survival and overall survival. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e208.	0.2	0
39	Influence of Renal Impairment and Genetic Risk Factors on Response to Induction Therapy in the HD4 and MM5 Trials of the GMMG. Blood, 2014, 124, 4777-4777.	0.6	0
40	Targeted Sequencing of Relapsed/Refractory Myeloma Patients Identifies an Enrichment of Mutations in Cereblon and MAPK Pathways. Blood, 2015, 126, 723-723.	0.6	0
41	Impact of Severe Infections during Induction Therapy on Dosage, Response and Survival in Newly Diagnosed Multiple Myeloma - a Subgroup Analysis from the Randomized Phase III Trial GMMG-HD4. Blood, 2015, 126, 3187-3187.	0.6	0
42	Abstract 2283: Molecular signaling in multiple myeloma: association of RAS/RAF mutation status and MAPK pathway activation in primary myeloma patient biopsies. , 2016, , .		0
43	Analysis of Long-Term Survival in Multiple Myeloma Patients after First-Line Autologous Stem Cell Transplantation: Impact of Clinical Risk Factors and Duration of Response. Blood, 2016, 128, 4649-4649.	0.6	0
44	Prediction of Early Death and Severe Infections during Novel Agent-Based Induction Therapy in Newly-Diagnosed Multiple Myeloma: An Intergroup Analysis from the German Speaking Myeloma Multicenter Group, the Dutch-Belgian Cooperative Trial Group for Hematology Oncology Foundation and the European Myeloma Network. Blood, 2021, 138, 3792-3792.	0.6	0
45	Impact of Novel Therapies on CD4-T-Cell-Numbers and Infectious Complications in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2020, 136, 14-14.	0.6	0